SecBot SecBot
8-K ·Filed Feb 24, 2026

CDNA

CareDx, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001217234-26-000015
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue acceleration and solid 2026 guidance suggest improving momentum. The CFO transition is routine corporate governance. Traders should monitor whether the company can achieve its 2026 guidance range, particularly given the $7.5M Medicare LCD headwind mentioned.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$18.46
T+0 close · Feb 24, 2026 · via day close
Latest settled
+14.57%
T+60 · $21.15
Vs SPY
+7.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $18.46entry
  2. T+1 · 9mo ago +1.95%α +2.50% · $18.82
  3. T+5 · 9mo ago +3.25%α +4.35% · $19.06
  4. T+20 · 8mo ago −2.06%α +3.18% · $18.08
  5. T+60 · 6mo ago +14.57%α +7.62% · $21.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CareDx reported strong Q4 and full-year 2025 financial results with 25% YoY revenue growth in Q4 and 14% for the full year. The company issued 2026 revenue guidance of $420M-$444M and announced CFO transition, with Keith Kennedy appointed as new CFO following Nathan Smith's resignation. Despite GAAP net losses, non-GAAP profitability improved and cash flow remained strong.

Key Financial Metrics

Revenue
$379.8M
+14.0% YoY
Adj. EPS
$0.58
GAAP: $-0.40
Guidance
$420M-$444M
initiated
Gross Margin
68%

Key Facts

  • Q4 2025 revenue: $108M (+25% YoY), Full-year 2025 revenue: $380M (+14% YoY)
  • GAAP net loss: $4M in Q4 2025 vs. $88M net income in Q4 2024 (due to $96M litigation reversal in 2024)
  • Non-GAAP net income: $6M in Q4 2025, $32M for full-year 2025
  • 2026 revenue guidance: $420M-$444M, Adjusted EBITDA: $30M-$45M
  • CFO transition: Keith Kennedy appointed, Nathan Smith resigned
  • Strong cash flow: $21.4M from operations in Q4, $42M for full year

Financial Impact

Revenue growth accelerating to 25% in Q4 2025 from 14% full-year growth, with 2026 guidance implying 10.5%-17.4% growth. Non-GAAP profitability maintained despite GAAP losses.

revenueepscashFlowguidance

Segment Breakdown

SegmentRevenueGrowth
Testing services$274.5M+10.0%
Patient and digital solutions$56.9M+31.0%
Product$48.4M+19.0%

Risk Factors

  • GAAP net losses in 2025 ($21M) despite revenue growth
  • 2026 guidance range is wide ($30M-$45M adjusted EBITDA)
  • Medicare LCD expected to impact 2026 revenue by $7.5M
  • CFO transition could create temporary execution risk

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001217234-26-000015
Document: cdna-20260224.htm0001217234-26-000015
Document: 0001217234-26-000015-index-headers.html0001217234-26-000015
Document: 0001217234-26-000015-index.html0001217234-26-000015
Document: 0001217234-26-000015.txt0001217234-26-000015

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026